← Back to Search

Monoclonal Antibodies

SHR-8068 in combination with adebrelimab for Non-Small Cell Lung Cancer

Phase 1 & 2
Recruiting
Research Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

To evaluate the tolerability and safety of SHR-8068 in combination with adebrelimab in subjects with advanced NSCLC To evaluate the efficacy of SHR-8068 in combination with adebrelimab and platinum-based chemotherapy in subjects with advanced NSCLC

Eligible Conditions
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Group I: SHR-8068 in combination with adebrelimab and platinum-based chemotherapyExperimental Treatment1 Intervention
Group II: SHR-8068 in combination with adebrelimabExperimental Treatment1 Intervention
Group III: Adebrelimab in combination with platinum-based chemotherapyExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Lead Sponsor
46 Previous Clinical Trials
8,435 Total Patients Enrolled
~77 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top